EW

Edwards Lifesciences

$107.11

-0.04%
Nov 16, 2026
Bobby Quantitative Model
Edwards Lifesciences is a global medical device company focused on structural heart disease, designing and marketing surgical tissue heart valves, transcatheter aortic valve replacement (TAVR) systems, and transcatheter mitral and tricuspid therapies, with roughly 60% of sales generated outside the US. Spun off from Baxter International in 2000, the firm has established itself as the clear market leader in transcatheter heart valves, a position built on clinical evidence, physician training, and a deep pipeline in structural heart interventions. The current investor narrative centers on a powerful beat-and-raise cycle — Q3 2026 revenue grew 10.5% year over year to $1.72 billion with EPS of $0.53 — amplified by a US agency proposal to broaden and simplify Medicare coverage for TAVR procedures, a direct volume catalyst for the category leader. That regulatory tailwind, combined with accelerating transcatheter mitral and tricuspid adoption and a balance sheet carrying over $3.1 billion in cash, has driven the stock to fresh 52-week highs and reframed the debate from procedure recovery toward durable, multi-year structural growth.

People also watch

Abbott Laboratories

Abbott Laboratories

ABT

Analysis
Medtronic plc

Medtronic plc

MDT

Analysis
Stryker Corporation

Stryker Corporation

SYK

Analysis
Boston Scientific

Boston Scientific

BSX

Analysis
GE HealthCare

GE HealthCare

GEHC

Analysis

BobbyInvestment Opinion: Should I buy EW Today?

Rating: Hold (with a constructive bias). The core thesis is that Edwards is a high-quality structural heart franchise executing a genuine beat-and-raise cycle — Q3 2026 revenue up 10.46% to $1.7155 billion with EPS of $0.53 — but after a 23.9% one-month surge to $107.15, the stock has essentially caught up to the Street's $113.39 average target, leaving only about 5.8% implied upside against a $84 low target roughly 22% below the current price. The consensus 'buy' (25 Buy, 4 Hold, 1 Sell; recommendation mean 1.53) confirms the business quality but not the entry point.

Supporting evidence is strong on fundamentals: revenue grew 10.46% year over year with gross margin holding at 78.5% and TTM operating margin of 27.0%, TTM free cash flow of $1.424 billion (Q3 alone $506.7 million) funds R&D of $281.4 million per quarter internally, and the balance sheet carries $3.11 billion in cash at a debt-to-equity of just 0.068 with a current ratio of 3.72. The forward PE of 31.6x versus 46.3x trailing implies consensus EPS of $4.695 versus roughly $2.31 TTM — the Street expects earnings to more than double — while the 8.2x PS and 8.66x EV/Sales sit at a premium to the 20x–30x PE range typical of large-cap medtech peers. The $126 high target (about 18% upside) is the payoff if Medicare TAVR coverage expansion and the mitral/tricuspid ramp ($209.5 million in Q3) both deliver.

Three risks could invalidate the thesis: (1) the Medicare TAVR coverage proposal stalls or is narrowed, removing the primary catalyst behind the re-rating; (2) TAVR volumes fail to accelerate beyond the current 10.5% revenue pace, leaving the 46.3x trailing multiple exposed to compression toward the peer range; and (3) earnings quality remains uneven — Q2 net margin fell to 13.9% on a 53.6% effective tax rate and Q4 2025 net income collapsed to $91.2 million on $279.9 million of other expenses. This Hold would upgrade to Buy on a pullback toward the $94–$95 consolidation zone (forward PE near 28x) or on evidence of accelerating TAVR procedure volumes post-coverage, and would downgrade to Sell if revenue growth decelerates below 8% or the coverage proposal is materially restricted. Verdict: fairly valued to modestly overvalued relative to near-term fundamentals, but reasonably priced on forward earnings if the coverage catalyst converts.

Sign up to view all

EW 12-Month Price Forecast

Edwards is a quality structural heart franchise with a genuine beat-and-raise cadence, a fortress balance sheet, and a direct regulatory catalyst in the proposed Medicare TAVR coverage expansion — but the stock has already re-rated 23.9% in a month to $107.15, leaving only about 5.8% to the $113.39 average target. The forward PE of 31.6x is near the lower end of Edwards' historical range and implies the market expects solid but not heroic earnings growth, which is a more balanced setup than the 46.3x trailing multiple suggests. The 25-of-27 Buy consensus and the November 5 wave of reiterations confirm conviction, but the single Sell and four Holds reflect a minority view that the stock is fully valued after its run. I would upgrade to bullish on a pullback toward the $94–$95 consolidation zone or on evidence that Medicare coverage expansion is converting into measurable TAVR procedure acceleration, and would downgrade to bearish if the coverage proposal is materially restricted or revenue growth decelerates below 8%.

Historical Price
Current Price $107.11
Average Target $111.50
High Target $126.00
Low Target $84.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $113.39 and implied upside of +5.9% versus the current price.

Average Target

$113.39

30 analysts

Implied Upside

+5.9%

vs. current price

Analyst Count

30

covering this stock

Price Range

$84 - $126

Analyst target range

Buy
25 (83%)
Hold
4 (13%)
Sell
1 (3%)

Coverage is deep and overwhelmingly bullish: 27 analysts rate the stock, with 25 Buy, 4 Hold, and 1 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.53 (where 1.0 is a strong buy). The average target price of $113.39 implies roughly 5.8% upside from the current $107.15, a modest gap that reflects how quickly the stock has run to catch up with Street models. The consensus leans clearly bullish, and the recent institutional ratings flow — TD Cowen reiterating Buy on November 11 and a wave of Overweight/Outperform reiterations from JPMorgan, Barclays, Piper Sandler, RBC, Leerink, BTIG, Citigroup, and Truist on November 5 — confirms broad conviction following the Q3 print.\n\nThe target range of $84.00 to $126.00 is wide, spanning roughly -22% to +18% from the current price, which signals meaningful dispersion in assumptions. The high target of $126 likely embeds multiple expansion on accelerating TAVR volumes from Medicare coverage expansion plus a successful mitral/tricuspid ramp, while the low target of $84 prices in competitive pressure, slower procedure growth, or margin compression from R&D investment. The single Sell rating and four Holds suggest a small minority see the stock as fully valued after its 24% one-month move; with the average target only ~6% above the current price, the risk/reward has narrowed, and further upside likely requires either estimate revisions higher or a breakout above the $107.69 resistance level.

Drowning in data?

Find the real signal!

Bulls vs Bears: EW Investment Factors

The bull case currently holds stronger evidence: 25 of 27 analysts rate Buy, revenue is growing 10.5% with a beat-and-raise cadence, the balance sheet carries $3.11 billion in cash at 0.068 debt-to-equity, and a Medicare TAVR coverage proposal is a direct volume catalyst for the category leader. Momentum confirms the fundamental re-rating, with EW outperforming SPY by 26.2 points over one month and 29.5 points over six months. The bear case rests less on fundamentals than on price: at 46.3x trailing and 31.6x forward earnings, with the average target only 5.8% above the current price, the stock has already absorbed much of the good news. The single most important tension is whether the Medicare coverage expansion converts into measurable TAVR procedure acceleration over the next two to three quarters — if it does, forward estimates rise and the premium multiple is validated; if procedure growth merely tracks the current 10.5% revenue pace, the stock is fully valued and vulnerable to a de-rating toward the $84 low target.

Bullish

  • TAVR Medicare coverage expansion catalyst: A US agency proposal to broaden and simplify Medicare coverage for TAVR procedures directly expands the addressable patient pool for Edwards' core transcatheter heart valve franchise, which generated $1.2416 billion of Q3 revenue. As the clear category leader with entrenched physician training and clinical evidence, Edwards is the most direct beneficiary of any volume uplift. This is a structural, multi-year demand driver rather than a one-quarter event.
  • Beat-and-raise with 10.5% revenue growth: Q3 2026 revenue of $1.7155 billion grew 10.46% year over year from $1.5531 billion, with EPS of $0.53 versus $0.50 a year earlier. The April news flow confirms a beat-and-raise pattern, and consensus forward EPS of $4.695 versus roughly $2.31 TTM implies the Street expects earnings to more than double, a 32% compression from the 46.3x trailing PE to 31.6x forward.
  • Fortress balance sheet with $3.1B cash: Debt-to-equity of just 0.068, a current ratio of 3.72, and $3.11 billion in cash with zero interest expense give Edwards full self-funding capacity for R&D, buybacks, and bolt-on M&A. TTM free cash flow of $1.424 billion (Q3 alone $506.7 million) is roughly 2.9% of the $49.9 billion market cap per quarter, underscoring the cash-generative quality of the franchise.
  • Overwhelming analyst conviction: Of 27 analysts, 25 rate Buy against 4 Hold and 1 Sell, producing a recommendation mean of 1.53 and a consensus 'buy'. The average target of $113.39 implies 5.8% upside, and the November 5 wave of reiterations from JPMorgan, Barclays, Piper Sandler, RBC, Leerink, BTIG, Citigroup, and Truist confirms broad post-Q3 conviction. The $126 high target implies roughly 18% upside if the coverage expansion and mitral/tricuspid ramp play out.

Bearish

  • Premium valuation leaves no margin for error: At 46.3x trailing PE, 8.2x PS, 8.66x EV/Sales, and 33.3x EV/EBITDA, Edwards trades well above the 20x–30x PE range typical of large-cap medical device peers. The 78.1% gross margin and 27.0% operating margin justify a quality premium, but the multiple embeds flawless execution of the TAVR coverage and mitral/tricuspid ramp.
  • Analyst upside nearly exhausted: The average target of $113.39 sits only 5.8% above the current $107.15, meaning the stock has essentially caught up to Street models after its 24% one-month run. The single Sell and four Holds reflect a minority view that the stock is fully valued, and further upside now requires estimate revisions higher or a breakout above $107.69 resistance.
  • Earnings volatility and margin unevenness: Net margin swung from 23.1% in Q1 2026 to 13.9% in Q2 (depressed by a 53.6% effective tax rate) and 17.9% in Q3, while Q4 2025 net income collapsed to $91.2 million on $279.9 million of other expenses. ROE of 10.4% and ROA of 8.8% remain below historical peaks, showing the drag from lower-margin recent quarters.
  • Heavy R&D burden and sequential revenue dip: R&D spending of $281.4 million in Q3 alone (roughly 16.4% of revenue) is necessary to defend the mitral/tricuspid pipeline but pressures near-term margins. Revenue also dipped sequentially from Q2's $1.741 billion to Q3's $1.7155 billion, and the transcatheter mitral/tricuspid segment at $209.5 million remains small relative to the $1.2416 billion TAVR franchise.

EW Technical Analysis

Edwards is in a sustained, accelerating uptrend, with the stock up 24.4% over the past year and 25.6% year to date, and the current price of $107.15 sitting at 99.5% of its 52-week range ($74.66–$107.69) — essentially at the highs. That positioning signals strong momentum rather than a value opportunity, though it also leaves little margin for error and raises the risk of profit-taking near resistance. Notably, the stock has outperformed the S&P 500 by 12.2 percentage points over one year and 15.0 points year to date, confirming genuine relative strength rather than a beta-driven rally.\n\nShort-term momentum is decisively accelerating: the stock is up 23.9% in the past month versus a 2.3% decline for SPY, a 26.2-point relative-strength spread, and up 17.0% over three months against a 2.8% SPY decline. The 1-month gain exceeds the 1-year gain, indicating the trend is steepening rather than decelerating — a classic breakout signature, with the move from roughly $86 in late October to $107 in mid-November occurring on a sequence of higher highs. The 6-month change of 31.7% versus SPY's 2.1% underscores that this is a persistent, not episodic, re-rating.\n\nKey resistance sits at the 52-week high of $107.69, just $0.54 above the current price; a clean breakout would confirm the uptrend and likely invite momentum buyers, while failure here could trigger a retest of the $100 psychological level and then the $94–$95 consolidation zone from late October. Support is anchored at the 52-week low of $74.66, roughly 30% below current levels, with intermediate support near $86 where the stock traded in early September. The beta of 0.832 indicates the stock is about 17% less volatile than the market, which is favorable for position sizing but also means the recent 24% monthly surge is unusually large for this name and may warrant caution on chasing strength.

Beta

0.83

0.83x market volatility

Max Drawdown

-13.2%

Largest decline past year

52-Week Range

$75-$108

Price range past year

Annual Return

+24.1%

Cumulative gain past year

PeriodEW ReturnS&P 500
1m+23.7%-3.0%
3m+17.7%-3.6%
6m+29.1%-0.2%
1y+24.1%+10.1%
ytd+25.5%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

EW Fundamental Analysis

Revenue is growing at a healthy and stable pace: Q3 2026 revenue of $1.7155 billion rose 10.46% year over year from $1.5531 billion, following Q2's $1.741 billion and Q1's $1.6486 billion, with the trailing four quarters totaling roughly $6.8 billion. The transcatheter heart valve franchise is the engine, contributing $1.2416 billion, while transcatheter mitral and tricuspid therapies add $209.5 million — a smaller but strategically important growth vector. Sequentially, revenue dipped modestly from Q2 to Q3, but the year-over-year trajectory remains firmly positive, and the beat-and-raise pattern visible in the April news flow supports the case for continued mid-to-high single-digit to low-double-digit growth.\n\nProfitability is robust but uneven quarter to quarter: Q3 2026 net income was $307.5 million (17.9% net margin) on a 78.5% gross margin, up from $291.1 million a year earlier, while Q2 net income of $241.9 million was depressed by a 53.6% effective tax rate. Gross margin has been remarkably stable in the 77.6%–78.5% band across the last four quarters, consistent with the high-margin profile typical of premium medical device franchises, and the operating margin of 26.97% (TTM) reflects heavy but necessary R&D spending of $281.4 million in Q3 alone. The Q4 2025 quarter was an outlier with net income of just $91.2 million due to $279.9 million in other expenses, but the underlying operating margin of 23.6% that quarter confirms the core business remained solid.\n\nThe balance sheet is fortress-like: debt-to-equity of just 0.068, a current ratio of 3.72, and $3.11 billion in cash at the end of Q3 2026, against negligible interest expense. Free cash flow is strong at $1.424 billion TTM, with Q3 FCF of $506.7 million and Q2 FCF of $585.0 million, though Q1 was negative at -$21.1 million due to a $501.5 million working-capital outflow and $521.8 million of share repurchases. ROE of 10.4% and ROA of 8.8% are respectable but below the company's historical peaks, reflecting the drag from lower-margin recent quarters; nonetheless, the company funds growth, buybacks, and bolt-on acquisitions internally without external financing, a meaningful quality signal.

Quarterly Revenue

$1.7B

2026-09

Revenue YoY Growth

+10.5%

YoY Comparison

Gross Margin

78.5%

Latest Quarter

Free Cash Flow

$1.4B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Transcatheter Heart Valves
Transcatheter Mitral And Tricuspid Therapies

Open an Account, get $2 TSLA now!

Valuation Analysis: Is EW Overvalued?

Because net income is positive ($307.5 million in Q3), the PE ratio is the appropriate primary metric. The trailing PE of 46.3x compares with a forward PE of 31.6x, a 32% compression that implies the market expects earnings to grow substantially — consistent with consensus EPS of $4.695 versus the current TTM EPS of roughly $2.31. The PEG ratio of -0.63 is not meaningful given the distorted trailing earnings base, so the forward multiple is the more reliable anchor.\n\nOn a peer basis, the 46.3x trailing PE and 8.2x PS sit at a premium to the medical devices sector, where large-cap peers typically trade in the 20x–30x PE range; the 8.66x EV/Sales and 33.3x EV/EBITDA are also rich, though the 78.1% gross margin and 27.0% operating margin justify a quality premium. The premium is defensible if the TAVR coverage expansion and mitral/tricuspid ramp deliver the expected acceleration, but it leaves little room for execution missteps.\n\nHistorically, Edwards' PE has ranged from roughly 28x to 133x over the past several years, with the current 46.3x sitting in the middle-to-upper portion of that band; the PS ratio of 8.2x, however, is well below the 28x–60x levels seen in 2021–2024, reflecting the post-2024 earnings normalization and suggesting the stock is not stretched on a sales basis. The forward PE of 31.6x is near the lower end of the historical range, implying the market is pricing in solid but not heroic growth — a more balanced setup than the trailing multiple alone would suggest.

PE

46.3x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 27x~60x

vs. Industry Avg

26.4x

Industry PE ~26.4x*

EV/EBITDA

33.3x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on valuation dependence rather than balance-sheet stress. Edwards carries debt-to-equity of only 0.068 and $3.11 billion in cash, so solvency is not a concern, but the 46.3x trailing PE and 8.66x EV/Sales require continued earnings expansion to justify the price. Earnings quality is uneven: Q2 2026 net income of $241.9 million was hit by a 53.6% effective tax rate, and Q4 2025 net income fell to $91.2 million on $279.9 million of other expenses, showing that non-operating items can swing reported results materially. Revenue concentration is another risk — the transcatheter heart valve franchise at $1.2416 billion dwarfs the $209.5 million mitral/tricuspid segment, so any TAVR deceleration would hit the consolidated growth rate disproportionately. Finally, R&D of $281.4 million in Q3 (about 16.4% of revenue) must be sustained to defend the pipeline, capping margin expansion even as revenue grows. Market and competitive risks are dominated by multiple compression. At 46.3x trailing and 31.6x forward earnings versus a 20x–30x large-cap medtech peer range, any slowdown in procedure growth or a competitive TAVR entrant could compress the multiple toward the low end of Edwards' own 28x–133x historical band. The beta of 0.832 means the stock is about 17% less volatile than the market, but that also makes the recent 24% one-month surge statistically unusual and vulnerable to reversal; the stock is up 23.9% in a month while SPY fell 2.3%, a 26.2-point spread that often precedes mean reversion. Regulatory risk cuts both ways: the Medicare TAVR coverage proposal is a tailwind if finalized, but any delay, restriction, or narrower-than-expected coverage criteria would remove the primary catalyst behind the recent re-rating. With roughly 60% of sales outside the US, currency and foreign reimbursement dynamics add another layer of sensitivity. The worst-case scenario is a catalyst reversal combined with multiple compression: the Medicare coverage proposal stalls or is narrowed, Q4 TAVR volumes fail to accelerate, and the stock de-rates from 46.3x toward the peer range while estimates are trimmed. In that chain, the price could fall toward the $84 analyst low target, roughly -22% from $107.15, and in a deeper risk-off move toward the $74.66 52-week low, about -30%. The historical max drawdown of -13.19% shows the stock's recent downside has been contained, but that figure was recorded during an uptrend and understates the risk from a fully priced 52-week high. Investors chasing at $107.15 face a realistic -22% to -30% downside against roughly 6% to 18% upside to the average and high targets, an unfavorable near-term skew.

FAQ

Ranked by severity: first, valuation and multiple-compression risk — at 46.3x trailing and 31.6x forward earnings, any deceleration could de-rate the stock toward the peer range and the $84 low target, about -22%. Second, regulatory/catalyst risk — the Medicare TAVR coverage proposal is the primary driver of the recent re-rating, and a delay, restriction, or narrower-than-expected criteria would remove that support. Third, earnings-quality and concentration risk — Q2 2026 net margin fell to 13.9% on a 53.6% effective tax rate and Q4 2025 net income collapsed to $91.2 million on $279.9 million of other expenses, while the $1.2416 billion TAVR franchise dwarfs the $209.5 million mitral/tricuspid segment. Fourth, macro and currency risk — about 60% of sales are outside the US, and with a beta of 0.832 the recent 24% monthly surge is statistically unusual and vulnerable to mean reversion.

The base case (55% probability) targets $105–$118, assuming revenue growth holds in the 9%–11% range, gross margin stays in the 77.6%–78.5% band, and the stock tracks toward the $113.39 average target as forward EPS of $4.695 is delivered. The bull case (25%) targets $120–$126 if Medicare coverage is finalized with broad criteria and TAVR volumes accelerate, while the bear case (20%) targets $84–$95 if coverage is delayed or narrowed and the multiple compresses toward peers. The base case is most likely because it requires only continuation of the current 10.46% trajectory rather than an acceleration; the key assumption is that the coverage decision is finalized without materially restrictive criteria.

On trailing metrics EW looks expensive: 46.3x PE, 8.2x PS, 8.66x EV/Sales, and 33.3x EV/EBITDA, all at a premium to the 20x–30x PE range typical of large-cap medtech peers. The forward PE of 31.6x tells a more balanced story, implying consensus EPS of $4.695 versus roughly $2.31 TTM — the Street expects earnings to more than double, a 32% compression in the multiple. That forward level sits near the low end of Edwards' historical 28x–133x PE band, and the 8.2x PS is well below the 28x–60x seen in 2021–2024. The market is paying a quality premium that assumes solid but not heroic growth; the stock looks fairly valued to modestly overvalued on near-term numbers, and only undervalued if the coverage catalyst converts into accelerating procedure volumes.

The risk/reward is balanced rather than compelling at $107.15. On the positive side, 25 of 27 analysts rate Buy with a recommendation mean of 1.53, revenue is growing 10.46% year over year, TTM free cash flow is $1.424 billion, and debt-to-equity is only 0.068 — a high-quality franchise with a genuine Medicare TAVR coverage catalyst. But the average target of $113.39 implies just 5.8% upside, while the $84 low target implies roughly -22% downside, and the stock already sits at 99.5% of its 52-week range after a 23.9% one-month move. It is a reasonable buy for long-horizon investors who can add on weakness toward the $94–$95 consolidation zone, and a poor entry for anyone chasing the breakout at resistance of $107.69.

EW is better suited to a long-term hold of at least 12–24 months than to short-term trading. The business is a durable structural heart franchise with 10.46% revenue growth, 78.5% gross margins, $1.424 billion TTM free cash flow, and a fortress balance sheet, and the Medicare coverage catalyst plus the mitral/tricuspid ramp are multi-year drivers rather than one-quarter events. However, the stock pays no dividend (0% yield) and trades at 31.6x forward earnings near its 52-week high, so near-term returns depend on estimate revisions and the coverage decision — a binary event that makes short-term positioning speculative. A beta of 0.832 keeps volatility moderate, but the 23.9% one-month gain raises chase risk; investors should size positions for a 12–24 month horizon and consider adding on pullbacks toward $94–$95.